Evidence map›Paper›PMID 30753101›Full record

Trial reportAmerican journal of respiratory and critical care medicine2019

Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.

Stephanie Ascough, Iris Vlachantoni, Mohini Kalyan, Bert-Jan Haijema, Sanna Wallin-Weber, Margriet Dijkstra-Tiekstra, Muhammad S Ahmed, Maarten van Roosmalen, Roberto Grimaldi, Qibo Zhang and 3 more

Open access · greenAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025
    Pooled it
  2. Vaccines for the common cold.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Antigen Delivery Systems: Past, Present, and Future.Biomolecules & therapeutics · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Stephanie Ascough1Section of Infectious Diseases and Immunity, Department of Medicine, and.
Iris Vlachantoni2Section of Respiratory Infections, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Mohini Kalyan1Section of Infectious Diseases and Immunity, Department of Medicine, and.
Bert-Jan Haijema3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Sanna Wallin-Weber3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Margriet Dijkstra-Tiekstra3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Muhammad S Ahmed4Department of Clinical Infection, Microbiology, and Immunology, University of Liverpool, Liverpool, United Kingdom.
Maarten van Roosmalen3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Roberto Grimaldi3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Qibo Zhang4Department of Clinical Infection, Microbiology, and Immunology, University of Liverpool, Liverpool, United Kingdom.
Kees Leenhouts3Mucosis B.V., represented by trustee Mr. Holtz, LLM, Bout Advocaten, Groningen, and Virtuvax B.V., Groningen, the Netherlands; and.
Peter J Openshaw2Section of Respiratory Infections, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Christopher Chiu1Section of Infectious Diseases and Immunity, Department of Medicine, and.ORCID 0000-0003-0914-920X
Dialyse Centrum Groningen · NLLung Institute · USUniversity of Liverpool · GB

Funding

Medical Research Council MC_PC_17220Medical Research Council MR/R005982/1Wellcome TrustWellcome Trust WT108516
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunogenicity, VaccineAdministration, IntranasalAdolescentAdultAntibodies, ViralDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansImmunization, SecondaryImmunoglobulin AMaleMiddle AgedNasal MucosaRespiratory Syncytial Virus InfectionsAntibodies, ViralImmunoglobulin ARespiratory Syncytial Virus Vaccinesclinical trialimmunologymucosalrespiratoryvirus

Identifiers

PMID30753101
PMCPMC6701032
OpenAlexW2912205029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.